READ MORE: PICTURES: Record-breaking attendance at Regeneron Great Limerick Run Their first foray ... the entire Darkness into Light movement, building on the creative fundraising we started ...

Me has faced an uncertain future after struggles to find a profitable business model and privacy concerns related to ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

Regeneron currently manufactures bulk drug products and materials at its facilities in Rensselaer, New York, and Limerick, Ireland, according to an investor filing. More than 80% of its workforce ...

Approval by the cabinet this week for the construction of what would be Limerick's tallest building has been described as a pivotal moment for the Opera Square project and the wider Limerick region.

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to help manufacture its medicines in the US, as the threat of tariffs looms ...

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Tuesday reported first-quarter profit of $808.7 million. The Tarrytown, New York-based company said it ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has inked a $3B deal with contract drug developer FUJIFILM Diosynth Biotechnologies (OTCPK:FUJIY) to boost production of its biologic medicines. The ...

Regeneron Pharmaceuticals (REGN) reported its first-quarter 2025 earnings, revealing a miss on both earnings and revenue expectations. The company posted earnings per share (EPS) of $8.22, falling ...

Dupixent continued to show robust growth, building on its momentum from the ... and potential delays in key product approvals. Regeneron faced mixed results in Q1 2025 with challenges in its ...

Regeneron has since re-filed the BCMAxCD3 drug in the U.S., and it's now awaiting a July 10 decision target date. With linvoseltamab's delayed arrival in the U.S., the multiple myeloma bispecific ...